Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 3/20 | 0.53 |
| ▸ | SYK | P43405 | 13/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4766314 | 0.84 | SYK (0.71) | CDK2SYK | |
| SCHEMBL4769132 | 0.82 | SYK (0.64) | CDK2SYKLRRK2 | |
| SCHEMBL4763434 | 0.81 | SYK (0.67) | SYKLRRK2AURKA | |
| SCHEMBL4764044 | 0.81 | SYK (0.66) | CDK2SYKLRRK2AURKA | |
| SCHEMBL5723541 | 0.80 | CDK2 (0.50) | CDK2AURKA | |
| SCHEMBL4775395 | 0.79 | SYK (0.60) | CDK2SYKLRRK2AURKA | |
| SCHEMBL4770588 | 0.79 | SYK (0.56) | SYKLRRK2AURKA | |
| SCHEMBL4772623 | 0.74 | SYK (0.54) | SYKLRRK2AURKA | |
| SCHEMBL4769208 | 0.73 | SYK (0.53) | SYKLRRK2AURKA | |
| SCHEMBL4765289 | 0.72 | CCNA2 (0.57) | CDK2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303496-B9 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-19 | — | — | EP | claimed |
| EP-1303496-B1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-12 | — | — | EP | claimed |
| US-6908920-B2 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2005-06-21 | — | — | US | claimed |
| US-20030216406-A1 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216406-A1 | Pyrimidine derivatives | TYMP, TYMS, CCNT1 | CDK2 24/4885SYK 1334/4885LRRK2 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.